UPDATE
: 2019.2.15 ±Ý 17:56
óÀ½À¸·Î
·Î±×ÀÎ
ȸ¿ø°¡ÀÔ
¸ÞµðÄ«¿î½½
Medi pharm IN
ÇÐȸ IN
Observation
Medi Council
Clinical Çмú Selection
Pharmacy Council
Á¾ÇÕ¡¤¿ÀÇǴϾð
ÇàÁ¤¡¤¹ý·É¡¤Á¤Ã¥
Global
Issue '¸®´õ½Ê'
±¸µ¶½Åû
Àüü±â»çº¸±â
¸ð¹ÙÀÏÀ¥
»ó´Ü¿©¹é
񃯇
(Àüü 66°Ç)
Á¦¸ñº¸±â
Á¦¸ñº¸±â
Á¦¸ñ+³»¿ë
Multiple Cell Therapy Collaborations to Advance the Company¡¯s Novel Immuno-Oncology Portfolio
Takeda Pharmaceutical Company Limited (¡°Takeda¡±) (TSE: 4502) today announce...
¶óÀÎ
Vargatef plus docetaxel could be an option after failure of immunotherapy in lung cancer
Boehringer Ingelheim announced today the first interim results of VARGADO, ...
¶óÀÎ
Sanofi Appoints Eun-Ju Kim as Head of HR in Korea
Nov. 27, 2018, Seoul –Sanofi-aventis Korea(County Chair: kay Bay, her...
¶óÀÎ
¶óÀÎ
Takeda to Present Data During 60th American Society of Hematology Annual Meeting on Wide Array of Treatment Needs for Blood Cancers
Takeda Pharmaceutical Company Limited (TSE: 4502) announced that it will pr...
¶óÀÎ
Boehringer Ingelheim and Lilly present full results of Trajenta¡¯s CARMELINA cardiovascular outcome trial
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today presented ...
¶óÀÎ
Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases
Boehringer Ingelheim and Tsinghua University in Beijing announce a collabor...
¶óÀÎ
¶óÀÎ
Takeda Announces Phase 3 Trial of ALUNBRIG Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib in Patients with ALK+ Advanced NSCLC Who are ALK
Takeda Pharmaceutical Company Limited (TSE: 4502) announced that the global...
¶óÀÎ
Phase 3 Trial of NINLARO as Maintenance Therapy Met Primary Endpoint Demonstrating Statistically Significant Improvement in Progression-Free Survival in Patients with Multiple Myeloma Post
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the ...
¶óÀÎ
South Korea¡¯s National Soccer Team Prepared 2018 Russia World Cup with Vaccination
Sanofi Pasteur in Korea(General Manager: Baptiste de Clarens) announced tha...
¶óÀÎ
¶óÀÎ
Boehringer Ingelheim R&D Pushes to Transcend Disease Boundaries
Family-owned pharmaceutical company Boehringer Ingelheim today presented it...
¶óÀÎ
Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than Doubling Funding to 250 M¢æ
Boehringer Ingelheim today announced an increase in funding for its corpora...
¶óÀÎ
AstraZeneca¡¯s Calquence Shows Potential in Chronic Lymphocytic Leukaemia Trials
AstraZeneca and Acerta Pharma, its haematology research and development cen...
¶óÀÎ
¶óÀÎ
New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases
(Business Wire/Korea Newswire) AstraZeneca today presented new data from a ...
¶óÀÎ
Takeda Initiates Phase 1 Clinical Trial of Zika Vaccine Candidate
(Business Wire/Korea Newswire) Takeda Pharmaceutical Company Limited [TSE: ...
¶óÀÎ
Boehringer Ingelheim Makes Many of Its Best Molecules Openly Available to the Scientific Community Via opnMe.com To Unlock Their Full Potential
(Business Wire/Korea Newswire) Boehringer Ingelheim today announced the lau...
¶óÀÎ
Takeda¡¯s Dengue Vaccine Candidate Associated with Reduced Incidence of Dengue in Children and Adolescents; New 18-Month Interim Phase 2 Data Published in The Lancet Infectious Diseases
(Business Wire/Korea Newswire) Takeda Pharmaceutical Company Limited (TSE: ...
¶óÀÎ
Janssen¡¯s New Darunavir-Based Single Tablet Regimen SYMTUZA Shows Positive Outcome in Treatment of Antiretroviral-Naïve HIV Patients
Janssen¡¯s new once-daily, single tablet combination therapy SYMTUZA® (d...
¶óÀÎ
FASLODEX(FULVESTRANT) RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN COMBINATION WITH PALBOCICLIB
AstraZeneca today announced that the Committee for Medicinal Products for H...
¶óÀÎ
IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to ¡®listen for the sounds of IPF¡¯
IPF is a progressive and debilitating disease which causes continual and ir...
¶óÀÎ
Janssen Receives Positive CHMP Opinion for SYMTUZA¢â The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV
Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) ...
-
1
2
3
4
-
Back to Top